Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

Trial-in-progress poster presentation provides overview of first-in-human Phase 1/2 clinical trial in participants with severe sickle cell disease designed to evaluate safety, efficacy and pharmacodynamics of GPH101 Initial proof-of-concept data from